“The important social distancing measures for COVID-19 have created a number of challenges for people with cancer, including keeping to planned treatment schedules,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “Today’s approval of an every six-week dosing schedule for KEYTRUDA gives doctors an option to reduce how often patients are at the clinic for their treatment.”Immune-mediated adverse reactions, which may be severe or fatal, can occur with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and renal dysfunction, severe skin reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation (HSCT). Based on the severity of the adverse reaction, KEYTRUDA should be withheld or discontinued and corticosteroids administered if appropriate. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. For more information, see “Selected Important Safety Information” below.
During this unprecedented time, Merck is committed to ensuring our medicines and vaccines reach our patients and customers. This includes a number of new steps to support patients in the U.S. who may have lost their jobs and insurance coverage. To learn more about resources Merck has available for patients who need help during the COVID-19 pandemic and beyond, visit our information page. For more detail about Merck’s response to the COVID-19 pandemic, please visit www.merck.com/COVID-19.
Source: "FDA Approves Merck’S KEYTRUDA® (Pembrolizumab) For Use At An Additional Recommended Dose Of 400 Mg Every Six Weeks For All Approved Adult Indications". 2020. Investors.Merck.Com.